Nutritional support for liver diseases

D Jamioł-Milc, A Gudan, K Kaźmierczak-Siedlecka… - Nutrients, 2023 - mdpi.com
The liver is a key organ that is responsible for the metabolism of proteins, fats, and
carbohydrates and the absorption and storage of micronutrients. Unfortunately, the …

[HTML][HTML] Effect of dietary intervention, with or without cointerventions, on inflammatory markers in patients with nonalcoholic fatty liver disease: a systematic review and …

RL Hall, ES George, AC Tierney, AJ Reddy - Advances in Nutrition, 2023 - Elsevier
Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of disease from simple
steatosis to nonalcoholic steatohepatitis, with inflammatory cytokines and adipokines …

Patient-Derived Tumor Chemosensitization of GKB202, an Antrodia Cinnamomea Mycelium-Derived Bioactive Compound

TJ Li, TW Lin, SP Wu, HT Chu, YH Kuo, JF Chiou… - Molecules, 2021 - mdpi.com
Oral cancers, hepatocellular carcinoma, and colorectal cancers are the three most common
cancers, leading to 18,000 cases of cancer-related mortality in Taiwan per year. To bridge …

Nutritional supplementation for nonalcohol‐related fatty liver disease: a network meta‐analysis

O Komolafe, E Buzzetti, A Linden… - Cochrane Database …, 2021 - cochranelibrary.com
Background The prevalence of non‐alcohol‐related fatty liver disease (NAFLD) varies
between 19% and 33% in different populations. NAFLD decreases life expectancy and …

[HTML][HTML] Evaluating Bioactive-Substance-Based Interventions for Adults with MASLD: Results from a Systematic Scoping Review

D Handu, K Stote, T Piemonte - Nutrients, 2025 - mdpi.com
Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic
condition affecting a broad population. This review aimed to identify and summarize the …

Epidemiology and disease burden of non-alcoholic steatohepatitis in greater China: a systematic review

H Zou, Y Ge, Q Lei, COL Ung, Z Ruan, Y Lai… - Hepatology …, 2022 - Springer
Background Non-alcoholic steatohepatitis (NASH) is a progression of non-alcoholic fatty
liver disease. The increasing burden of NASH has become a major concern of public health …

A Botanical Drug Extracted From Antrodia cinnamomea: A First-in-human Phase I Study in Healthy Volunteers

YT Liao, KW Huang, WJ Chen… - Journal of the American …, 2023 - Taylor & Francis
Objective: LEAC-102 is an emerging drug extracted from the medicinal fungus Antrodia
cinnamomea (AC), which is traditionally used to ameliorate fatigue and liver disorders …

Evaluation of the potential of Ergostatrien‐3β‐ol for treating Sjögren's syndrome

PC Wu, YH Chao, X Zhang, TT Chen… - International Journal …, 2024 - Wiley Online Library
Abstract Aim Ergostatrien‐3β‐ol (EK100) is a bioactive compound found in the fruiting
bodies and mycelia of Antrodia cinnamomea and has anti‐inflammatory and …

Hepatoprotective effect of Antrodia Cinnamomea mycelia extract in subhealth Japanese adults: a randomized, double-blind, placebo-controlled clinical study

CY Ho, CM Kuan, PK Hsu - Journal of Dietary Supplements, 2023 - Taylor & Francis
Antrodia cinnamomea, a unique Taiwanese fungus (mushroom), has demonstrated the
hepatoprotective activities in animals with liver injury. Nevertheless, there are few studies …

[PDF][PDF] 樟芝發酵菌絲體用於預防乾眼症之功能性評估

徐瑞霞, 林定威, 朱心彤, 林培正, 張菡馨, 陳勁初 - 中醫藥雜誌, 2021 - nricm.edu.tw
樟芝(Antrodia cinnamomea) 為臺灣特有的真菌之一, 具有免疫調節及保護肝臟之生理活性.
然而, 目前尚未有樟芝應用於預防乾眼症的研究報導. 本試驗利用液態發酵培養樟芝菌絲體 …